Lantheus (LNTH) Stock Price, News & Analysis

Company Overview

Lantheus Holdings, Inc. is a life sciences company specializing in the development, manufacture and commercialization of innovative diagnostic imaging agents and radiopharmaceutical products. The company focuses on molecular imaging and targeted radiotherapeutics, seeking to advance precision medicine through noninvasive technologies that help clinicians detect, diagnose and treat disease.

Its product portfolio spans several key imaging modalities and therapeutic areas. Lantheus markets Definity, an ultrasound contrast agent used in echocardiography, and operates the TechneLite™ generator system for producing technetium-99m, a critical isotope in nuclear medicine. The company’s precision diagnostics franchise includes Gallium Ga-68 DOTATATE injection (NETSPOT®) for imaging neuroendocrine tumors and piflufolastat F-18 injection (PYLARIFY®) for PET scanning of prostate cancer. On the therapeutic side, Lantheus offers iobenguane I-131 injection (AZEDRA®) for the treatment of rare neuroendocrine tumors, reflecting its growing commitment to radiotherapeutics.

Originally founded in the mid-20th century, Lantheus entered its current form following the 2006 acquisition of DuPont’s medical imaging business. The company accelerated its expansion into radiopharmaceuticals with the 2021 acquisition of Progenics Pharmaceuticals, adding both diagnostic and therapeutic assets to its pipeline. Under the leadership of President and Chief Executive Officer Michael M. Weingarten and a seasoned management team, Lantheus has pursued strategic investments in research, manufacturing and regulatory capabilities.

Lantheus maintains a global footprint with manufacturing facilities, research centers and distribution networks across North America and Europe. Its products are supplied to academic medical centers, hospitals and specialty clinics, and the company continues to invest in scalable production and new product development to broaden access to molecular imaging and targeted therapy solutions worldwide.

Key Stats

• Today's Range: $83.10 to $85.31
• 50-Day Range: $73.86 to $108.74
• 52-Week Range: $73.11 to $126.89
• Volume: 814,865 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $5.80 billion
• P/E Ratio: 23.82
• Dividend Yield: N/A
• Price Target: $130.50
• Consensus Rating: Buy

Lantheus Stock Analysis - MarketRank™

Lantheus scored higher than 86% of companies evaluated by MarketBeat, and ranked 117th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lantheus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 4.99%

Earnings Growth

Earnings for Lantheus are expected to grow by 4.99% in the coming year, from $6.01 to $6.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantheus is 23.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantheus is 23.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.58.

Price to Book Value per Share Ratio

Lantheus has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.60% of the float of Lantheus has been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Lantheus has recently increased by 14.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantheus does not currently pay a dividend.

Dividend Growth

Lantheus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.67

Percentage of Shares Shorted

13.60% of the float of Lantheus has been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Lantheus has recently increased by 14.27%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.40

News Sentiment

Lantheus has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Lantheus this week, compared to 10 articles on an average week.

Search Interest

Only 5 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,002,651.00 in company stock.

Percentage Held by Insiders

Only 1.50% of the stock of Lantheus is held by insiders.

Percentage Held by Institutions

99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LNTH Stock Analysis - Frequently Asked Questions

How have LNTH shares performed this year?

Lantheus' stock was trading at $89.46 at the beginning of the year. Since then, LNTH stock has decreased by 6.3% and is now trading at $83.83.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, May, 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by $0.11. Lantheus's quarterly revenue was up .8% compared to the same quarter last year.
Read the conference call transcript.

When did Lantheus IPO?

Lantheus (LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Top institutional investors of Lantheus include Reinhart Partners LLC. (2.03%), Harbor Capital Advisors Inc. (0.27%), Silverberg Bernstein Capital Management LLC (0.04%) and E. Ohman J or Asset Management AB (0.03%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden and Minnie Baylor-Henry.
View institutional ownership trends.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LNTH
• CIK: 1521036
• Web: www.lantheus.com
• Phone: (978) 671-8001
• Fax: 978-671-8860
• Employees: 700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lantheus: $130.50
• High Price Target: $175.00
• Low Price Target: $109.00
• Potential Upside/Downside: +53.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.52
• Trailing P/E Ratio: 24.11
• Forward P/E Ratio: 14.12
• P/E Growth: N/A
• Net Income: $312.44 million
• Net Margins: 16.55%
• Pretax Margin: 23.18%
• Return on Equity: 36.99%
• Return on Assets: 20.55%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 5.74
• Quick Ratio: 5.46

Sales & Book Value

• Annual Sales: $1.53 billion
• Price / Sales: 3.83
• Cash Flow: $7.30 per share
• Price / Cash Flow: 11.62
• Book Value: $15.65 per share
• Price / Book: 5.42

Miscellaneous

• Outstanding Shares: 69,190,000
• Free Float: 68,148,000
• Market Cap: $5.87 billion
• Optionable: Optionable
• Beta: 0.12